DrugPatentWatch Database Preview➤ Get the DrugPatentWatch Daily Briefing
« Back to Dashboard
Summary for Patent: 5,618,702
|Title:||PCR amplification of mRNA|
|Abstract:||A method for producing a contaminating DNA free PCR amplification product of mRNA is disclosed. The mRNA amplification product is of lower molecular weight and is readily separated, e.g., by gel electrophoresis, from any amplified cellular DNA contaminant.|
|Inventor(s):||Scanlon; Kevin J. (Pasadena, CA)|
|Assignee:||City of Hope (Duarte, CA)|
|Patent Claims:||1. A method for producing a substantially contaminating DNA free PCR amplification product of a mRNA from a cellular DNA contaminated gene transcript, the method comprising:
(a) providing a gene transcript mRNA,
said gene having an intron flanked by first and second exons,
said gene transcript mRNA being contaminated with template DNA from which said mRNA was transcribed,
said mRNA having a first portion complementary only to a sequence of said first exon and an abutting second portion complementary only to a sequence of said second exon;
(b) providing first and second PCR primers,
said first PCR primer being complementary to said first portion of said mRNA and, said second PCR primer being complementary to the completment of said abutting second portion of said mRNA;
(c) annealing said primers to said mRNA and thereafter,
(d) reacting said mRNA having said primers anealed thereto with reverse transcriptase to provide double stranded DNA, one strand of which has the sequence of said mRNA and the other strand of which is complementary to said sequence of said mRNA;
(e) reacting said double stranded DNA with said first and second primers in a PCR to simultaneously amplify (i) said double stranded DNA and (ii) said DNA contaminant to provide an amplification reaction product containing amplified double stranded DNA which has no sequence complementary to said intron and amplified DNA contaminant which includes said intron,
wherein said amplified double stranded DNA which has no sequence complementary to said intron is of substantially lower molecular weight than said amplified DNA contaminant which includes said intron; and
(f) utilizing the difference in molecular weights to separate said amplified double stranded DNA from said amplified DNA contaminant to produce a substantially contaminating DNA free PCR amplification product.
2. A method as defined by claim 1 in which said gene transcript is a transcript of a human oncogene.
3. A method as defined by claim 1 in which said gene transcript is a transcript of a human H-ras oncogene or a human c-myc oncogene or a human thymidylate synthase gene.
4. A method as defined by claim 1 in which said gene transcript is a transcript of a human c-myc gene.
5. A method as defined by claim 1 in which said transcript gene is a transcript of a human c-myc gene, said first primer has the sequence of SEQ ID NO: 1 and said second primer has the sequence of SEQ ID NO: 2.
6. A method as defined by claim 1 in which said gene transcript is a transcript of a human H-ras oncogene.
7. A method as defined by claim 1 in which said transcript gene is a transcript of a human H-ras gene, said first primer has the sequence of SEQ ID NO: 4 and said second primer has the sequence of SEQ ID NO: 5.
|Applicant||Tradename||Biologic Ingredient||Dosage Form||BLA||Number||Approval Date||Patent No.||Assignee||Estimated Patent Expiration||Status||Orphan||Source|
|Schering||INTRON A||interferon alfa-2b||VIAL||103132||001||1986-06-04||⤷ Free Forever Trial||City of Hope (Duarte, CA)||2014-04-08||RX||search|
|Schering||INTRON A||interferon alfa-2b||VIAL||103132||002||1986-06-04||⤷ Free Forever Trial||City of Hope (Duarte, CA)||2014-04-08||RX||search|
|Schering||INTRON A||interferon alfa-2b||VIAL||103132||003||1986-06-04||⤷ Free Forever Trial||City of Hope (Duarte, CA)||2014-04-08||RX||search|
|>Applicant||>Tradename||>Biologic Ingredient||>Dosage Form||>BLA||>Number||>Approval Date||>Patent No.||>Assignee||>Estimated Patent Expiration||>Status||>Orphan||>Source|
|Country||Patent Number||Estimated Expiration|
|Australia||1556188||⤷ Free Forever Trial|
|Australia||4197689||⤷ Free Forever Trial|
|Australia||633271||⤷ Free Forever Trial|
|Australia||639973||⤷ Free Forever Trial|
|>Country||>Patent Number||>Estimated Expiration|
Make Better Decisions: Try a trial or see plans & pricing
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.